Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

/PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...

Related Keywords

United States ,American ,David Sallman ,Davida Sallman ,Steven Harasym ,Helen Sabzevari ,Exchange Commission ,International Prognostic Scoring System ,Drug Administration ,Department Of Malignant Hematology ,American Cancer Society ,Precigen Inc ,Assistant Member ,Malignant Hematology ,Moffitt Cancer Center ,Research Institute ,Orphan Drug Designation ,Dose Level ,Stable Disease ,European Leukemianet ,Summary Objective Response Data ,Complete Response ,Advancing Medicine ,Acute Myeloid Leukemia ,Myelodysplastic Syndrome ,Sleeping Beauty ,Annual Report ,Key Statistics ,Precigen ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,